Sevabertinib

small molecule

Identifier: CI-DRUG-00000552
Entity page: /drug/sevabertinib ↗
Edges: 23

Neighbours: 5 cancers8 variants8 trials2 approvals
Drawn: 23 of 23 neighbours (cap 60); table lists every fetched edge

Accepted: cancer:<slug>, gene:<symbol>, variant:<slug>, drug:<slug>, trial:<NCT id>, or a bare CI id. Find slugs with search.

Most connectedLung Non-Small Cell Carcinoma 3,149 Malignant Colorectal Neoplasm 1,866 ABL1 298 EGFR 276 Imatinib 450 Dasatinib 321

Neighbourhood

Radial view

Focus at the centre; neighbours grouped by entity type. Click a node to re-centre the graph on it; ↗ opens the entity page. Hover a spoke for relationship, evidence level, cancer context and source.

Edges

Every edge, grouped by relationship

Source-native edges first (aggregated per neighbour, direction, evidence level and source), then derived registry links. Up to 15 per relationship (10 trials); “show all” raises one group to 200.

Relationship	Neighbour	Direction	Evidence level	Cancer context	Support	Claim	Source	Expand
Sevabertinib approved for …APPROVED_FOR3 of 2
→ approved for	Lung Non-Squamous Non-Small Cell Carcinomasubtype	supports	FDA ORIG	Lung Non-Squamous Non-Small Cell Carcinoma	1	Regulatory	openfda	graph →
→ approved for	FDA · US · 2026Efficacy supplement 2026-09-09 (see label)

Sevabertinib predicts response to …PREDICTS_RESPONSE_TO8 of 8
← predicts response to	ERBB2 Exon 20 Insertioninsertion	sensitivity	A	Lung Non-Small Cell Carcinoma	1	Curated	civic	graph →
← predicts response to	ERBB2 Kinase Domain Mutation	sensitivity	A	Lung Non-Small Cell Carcinoma	1	Curated	civic	graph →
← predicts response to	ERBB2 G776delinsLCindel	sensitivity	A	Lung Non-Small Cell Carcinoma	1	Curated	civic	graph →
← predicts response to	ERBB2 G776delinsVCindel	sensitivity	A	Lung Non-Small Cell Carcinoma	1	Curated	civic	graph →
← predicts response to	ERBB2 S310FSNV	sensitivity	A	Lung Non-Small Cell Carcinoma	1	Curated	civic	graph →
← predicts response to	ERBB2 V659ESNV	sensitivity	A	Lung Non-Small Cell Carcinoma	1	Curated	civic	graph →
← predicts response to	ERBB2 G778_P780dup	sensitivity	A	Lung Non-Small Cell Carcinoma	1	Curated	civic	graph →
← predicts response to	ERBB2 Y772_A775dupinsertion	sensitivity	A	Lung Non-Small Cell Carcinoma	1	Curated	civic	graph →

Sevabertinib investigated for …INVESTIGATED_FOR2 of 2
→ investigated for	Lung Non-Small Cell Carcinomasubtype 2 source records aggregated	supports	A	Lung Non-Small Cell Carcinoma	2	Curated	civic	graph →
→ investigated for	Neoplasmcancer_family	unknown	2	Neoplasm	1	Curated	chembl	graph →

Sevabertinib investigated in trials for …INVESTIGATED_IN_TRIALSderived3 of 3
→ investigated in trials for	Lung Non-Small Cell Carcinomasubtype 7 trials (1 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Lung Non-Small Cell Carcinoma	7	Observed	clinicaltrials	graph →
→ investigated in trials for	Malignant Neoplasm 1 trials (0 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Malignant Neoplasm	1	Observed	clinicaltrials	graph →
→ investigated in trials for	Solid Neoplasm 1 trials (1 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Solid Neoplasm	1	Observed	clinicaltrials	graph →

Sevabertinib studied in …STUDIED_INderived8 of 8
→ studied in	NCT06452277Phase 3 · recruiting A Study to Learn More About How Well Sevabertinib Works and How Safe it is Compared With Standard Treatment, in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2) · 8 trials list this drug (2 active)	—	—	Lung Non-Small Cell Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT06760819Phase 2 · recruiting A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2) · 8 trials list this drug (2 active)	—	—	Solid Neoplasm	1	Observed	clinicaltrials	graph →
→ studied in	NCT06761976available Expanded Access to Provide Sevabertinib (BAY 2927088) for the Treatment of Locally Advanced or Metastatic NSCLC With HER2 Mutation · 8 trials list this drug (2 active)	—	—	Malignant Neoplasm,Lung Non-Small Cell Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT06329895Phase 1 · completed A Study to Learn About How BAY2927088 Affects the Level of Dabigatran or Rosuvastatin in the Blood When These Drugs Are Taken Together in Healthy Participants · 8 trials list this drug (2 active)	—	—	Lung Non-Small Cell Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT06378658Phase 1 · completed A Study to Learn About How Food and Esomeprazole Affect the Level of BAY2927088 in the Blood When Taken Together in Healthy Participants · 8 trials list this drug (2 active)	—	—	Lung Non-Small Cell Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT06360211Phase 1 · completed A Study to Learn About How BAY2927088 Affects the Level of Midazolam in the Blood When Both Drugs Are Taken Together in Healthy Participants · 8 trials list this drug (2 active)	—	—	Lung Non-Small Cell Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT06221475Phase 1 · completed A Study to Learn How BAY2927088 is Taken up and Handled by the Body in Healthy Male Participants · 8 trials list this drug (2 active)	—	—	Lung Non-Small Cell Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT06348888Phase 1 · completed A Study to Learn About How Itraconazole and Carbamazepine Affect the Level of BAY2927088 in the Blood When These Drugs Are Taken Together by Healthy Participants · 8 trials list this drug (2 active)	—	—	Lung Non-Small Cell Carcinoma	1	Observed	clinicaltrials	graph →

Radial view

Every edge, grouped by relationship

Paths